A biotechnology company focused on developing cancer therapies.
2 AI-extracted insights from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Not enough scored insights about Tango Therapeutics in the last 30 days yet.
The 1 sources with the most insights about Tango Therapeutics on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
A major 10% owner sold $5.11 million worth of stock. Historically, the stock has fallen an average of 42% in the three months following this specific owner's sales, creating a very strong warning signal.
A 10% owner made an unscheduled sale, and this insider's previous sales have been followed by an average stock decline of over 40% within three months, a very strong bearish signal.
A major 10% owner sold $5.11 million worth of stock. Historically, the stock has fallen an average of 42% in the three months following this specific owner's sales, creating a very strong warning signal.
A 10% owner made an unscheduled sale, and this insider's previous sales have been followed by an average stock decline of over 40% within three months, a very strong bearish signal.
Other assets that creators frequently mention in the same content as Tango Therapeutics.
The most active sources covering Tango Therapeutics (TNGX) on Kazuha are @ceowatcher. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Tango Therapeutics (TNGX) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Tango Therapeutics (TNGX) most frequently also discuss CECE, MDU, ESTC, DHI, VRT. See the "Discussed alongside" section above for full asset pages.